Table 4.
Treatment-related adverse events
| n (%) | TACE plus apatinib plus camrelizumab (n = 80) | |
|---|---|---|
| All grade | Grade ≥ 3 | |
| Hand-foot skin reaction | 33 (41.3) | 5 (6.3) |
| Hypertension | 35 (43.8) | 6 (7.5) |
| Fatigue | 16 (20.0) | 2 (2.5) |
| Mouth ulcers | 5 (6.3) | 0 (0) |
| Proteinuria | 25 (31.3) | 1 (1.3) |
| Rash | 11 (13.8) | 0 (0) |
| Hoarseness | 4 (5.0) | 0 (0) |
| Gingival hamorrhage | 3 (3.8) | 0 (0) |
| Decreased appetite | 14 (17.5) | 0 (0) |
| Diarrhoea | 13 (16.3) | 2 (2.5) |
| Hypothyroidism | 15 (18.8) | 0 (0) |
| Hyperthyroidism | 3 (3.8) | 0 (0) |
| RCCEP | 16 (20.0) | 0 (0) |
| Myocarditis | 3 (3.8) | 1 (1.3) |
| Haemorrhage, upper GI | 3 (3.8) | 0 (0) |
RCCEP reactive cutaneous capillary endothelial proliferation, GI gastrointestinal tract